Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | The importance of treatment sequencing in CLL

Barbara Eichhorst • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia

Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, comments on the importance of sequencing treatments in patients with chronic lymphocytic leukemia (CLL) to improve the duration and quality of remission, and highlights the possibility of combining different agents. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Barbara Eichhorst

1:05
Risk-factors for Richter’s transformation
Barbara Eichhorst • 10 Dec 2023
2:01
Updated follow-up results of the Phase III GAIA/CLL13 trial
Barbara Eichhorst • 10 Dec 2023
2:08
CLL-RT1 trial: primary endpoint analysis of tislelizumab plus zanubrutinib in patients with RT
Barbara Eichhorst • 10 Dec 2023
1:14
Current trials of interest in CLL
Barbara Eichhorst • 7 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals